| Amal Therapeutics–Boehringer: investment, 201907 acquisition of Amal by Boehringer for up to €325m |
2019-07-15 |
| Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne |
2019-07-15 |
| Recursion Pharmaceuticals–SEVERAL: investment, 201907 financing round Series C $121m led by Baillie Gifford |
2019-07-15 |
| Galapagos–Gilead: investment, 201907 equity investment $1.1b at €140.59/share raising share from 12.3% to 22% as part of collab |
2019-07-14 |
| Gilead–Galapagos: drug research + development, 201907–202906 strategic 10y collab $3.9b upfront + $1.1b equity investment + milestones |
2019-07-14 |
| Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties |
2019-07-12 |
| BioTek Instruments–Agilent: investment, 201907– acquisition $1.165b incl anticipated tax benefits net $1.05b |
2019-07-11 |
| Microphyt–CEA Industrie: investment, 201907 financing round totalling €28.5m incl existing + co-investor Supernova Invest |
2019-07-11 |
| Microphyt–Demeter: investment, 201907 financing round totalling €28.5m incl existing + co-investor Demeter Partners |
2019-07-11 |
| Microphyt–France (govt): investment, 201907 financing round totalling €28.5m incl new + co-lead investor Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Irdi Soridec: investment, 201907 financing round totalling €28.5m incl existing + co-investor Irdi Soridec |
2019-07-11 |
| Microphyt–iXO Private Equity: investment, 201907 financing round totalling €28.5m incl new + co-investor iXO Private Equity |
2019-07-11 |
| Microphyt–Safilaro: investment, 201907 financing round totalling €28.5m incl new + co-investor Sofilaro |
2019-07-11 |
| Microphyt–SEVERAL: investment, 201907 financing round €28.5m co-led by Sofinnova Partners + Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Sofinnova: investment, 201907 financing round totalling €28.5m incl new + co-lead investor Sofinnova Partners |
2019-07-11 |
| Vasopharm–Bavaria (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Bayern Kapital |
2019-07-11 |
| Vasopharm–Creathor Ventures: investment, 201907 financing round totalling €9.5m incl new + co-investor Creathor Ventures |
2019-07-11 |
| Vasopharm–EF Investments: investment, 201907 financing round totalling €9.5m incl co-lead investor EF Investments |
2019-07-11 |
| Vasopharm–HeidelbergCapital: investment, 201907 financing round totalling €9.5m incl existing + co-lead investor HeidelbergCapital Private Equity |
2019-07-11 |
| Vasopharm–Hessen (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Future Capital |
2019-07-11 |
| Vasopharm–Optimum Strategic Communications: public relations, 201907 service existent by Optimum |
2019-07-11 |
| Vasopharm–SEVERAL: investment, 201907 financing round €9.5m co-led by HeidelbergCapital Private Equity + EF Investments |
2019-07-11 |
| Start Codon–Zyme Communications: public relations, 201907 service existent by Zyme |
2019-07-10 |
| BioNTech–BVCF Management: investment, 201907 financing round Series B totalling $325m incl co-investor BVCF Management |
2019-07-09 |
| BioNTech–Fidelity: investment, 201907 financing round Series B totalling $325m incl existing + lead investor Fidelity Management and Research |
2019-07-09 |
| BioNTech–Invus Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Invus |
2019-07-09 |
| BioNTech–Jebsen Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Jebsen Capital |
2019-07-09 |
| BioNTech–Mirae Asset: investment, 201907 financing round Series B totalling $325m incl co-investor Mirae Asset Financial Group |
2019-07-09 |
| BioNTech–Platinum Asset Management: investment, 201907 financing round Series B totalling $325m incl co-investor Platinum Asset Management |
2019-07-09 |
| BioNTech–Redmile Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Redmile Group |
2019-07-09 |
| BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by existing investor Fidelity Management and Research |
2019-07-09 |
| BioNTech–Steam Athena Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Steam Athena Capital |
2019-07-09 |
| BioNTech–Strüngmann Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investorStrüngmann Family Office |
2019-07-09 |
| Revolution Medicines–Casdin Capital: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Casdin Capital |
2019-07-09 |
| Revolution Medicines–Column Group: investment, 201907 financing round Series C totalling $100m incl existing + co-investor The Column Group |
2019-07-09 |
| Revolution Medicines–Nextech Invest: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Nextech Invest |
2019-07-09 |
| Revolution Medicines–Schroders: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Schroder Adveq |
2019-07-09 |
| Revolution Medicines–Third Rock Ventures: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Third Rock Ventures |
2019-07-09 |
| Breakpoint Therapeutics–Evotec: investment, 201907 first financing round totalling €30m incl co-investor Evotec |
2019-07-08 |
| Breakpoint Therapeutics–Medicxi: investment, 201907 first financing round totalling €30m incl lead investor Medicxi |
2019-07-08 |
| Breakpoint Therapeutics–Otsuka: investment, 201907 first financing round totalling €30m incl co-investor Taiho Ventures LLC |
2019-07-08 |
| Breakpoint Therapeutics–SEVERAL: investment, 201907 first financing round €30m for spin-out from Evotec led by Medicxi + incl Taiho Ventures + Evotec |
2019-07-08 |
| IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S |
2019-07-08 |
| IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al |
2019-07-08 |
| PMOD Technologies–Bruker Corp: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker |
2019-07-08 |
| Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 |
2019-07-05 |
| Citryll–BrightGene: investment, 201907 first closing of a targeted €15m financing round Series A incl investor BrightGene International Ltd |
2019-07-03 |
| Citryll–Curie Capital: investment, 201907 first closing of a targeted €15m financing round Series A incl investor Curie Capital |
2019-07-03 |
| Citryll–ModiQuest: investment, 201907 first closing of a targeted €15m financing round Series A incl investor ModiQuest BV |
2019-07-03 |
| Citryll–Netherlands (govt): investment, 201907 first closing of a targeted €15m financing round Series A incl investor BOM Brabant Ventures |
2019-07-03 |
| Citryll–SEVERAL: investment, 201907 first closing of targeted €15m financing round Series A with ModiQuest + BOM + BrightGene + Curie Capital |
2019-07-03 |
| Nosopharm–Evotec: antibiotics, 201907– collab €na pre-clinical developm of NOSO-502 + 2nd generation odilorhabdin |
2019-07-03 |
| Oncovita–Andrew Lloyd Associates: public relations, 201907 service existent by ALA |
2019-07-02 |
| Oncovita–Institut Pasteur: cancer immunotherapy, 201907– license excl ww €na for use of oncolytic measles virus platform for product developm + sale |
2019-07-02 |
| Oncovita–Institut Pasteur: investment, 201907 existent Institut Pasteur is shareholder of Oncovita |
2019-07-02 |
| Ahren Innovation Capital–SEVERAL: investment, 201907 closing of first fund Ahren LP in excells of £200m |
2019-07-01 |
| Antimicrobials Working Group–Entasis Therapeutics: antibiotics, 201907– collab existent Entasis is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–Iterum Therapeutics: antibiotics, 201907– collab existent Iterum is member of AWG |
2019-07-01 |
| Boehringer–Yuhan: GLP1R/FGF21R agonist, 201907– collab + license agreem for FGF21 $40m upfront + $830m milestones + royalties |
2019-07-01 |
| Century Therapeutics–Bayer: investment, 201907 financing round totalling $250m commitments incl $215m from Leaps by Bayer |
2019-07-01 |
| Century Therapeutics–Fujifilm: investment, 201907 financing round totalling $250m commitments incl co-investor Fujifilm Cellular Dynamics Inc |
2019-07-01 |
| Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI |
2019-07-01 |
| Century Therapeutics–Versant Ventures: investment, 201907 financing round totalling $250m commitments incl existing + co-investor Versant Ventures |
2019-07-01 |
| Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties |
2019-07-01 |
| Biodesix–Oncimmune: clinical proteomic cancer test, 201906– collab excl commercialisation of EarlyCDT Lung in US by Biodesix |
2019-06-28 |
| CryoTherapeutics–SEVERAL: investment, 201906 financing round Series B €7m incl equity + debt + non-dilutive cash advances |
2019-06-27 |
| Modag–Massa Investment: investment, 201906 financing round Series A totalling €12m incl lead investor Massa Investment AG |
2019-06-27 |
| Modag–SEVERAL: investment, 201906 financing round Series A €12m led by Massa Investment AG |
2019-06-27 |
| Modag–Trophic Communications: public relations, 201906 service existent by Trophic |
2019-06-27 |
| Velabs Therapeutics–SEVERAL: investment, 201906 financing round Series B €3m |
2019-06-27 |
| Evotec–SEVERAL: credit, 201906– promissory note €250m with lead arrangers Deutsche Bank + LBBW |
2019-06-26 |
| Sanifit–Alta Life Sciences: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Alta Life Sciences |
2019-06-26 |
| Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners |
2019-06-26 |
| Sanifit–Columbus Venture Partners: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Columbus Venture Partners |
2019-06-26 |
| Sanifit–Consilium: public relations, 201906 service existent by CSC |
2019-06-26 |
| Sanifit–Forbion: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Forbion Capital Partners |
2019-06-26 |
| Sanifit–Gilde Investment: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Gilde Healthcare |
2019-06-26 |
| Sanifit–HealthEquity: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor HealthEquity |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Sanifit–Ysios Capital: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Ysios Capital |
2019-06-26 |
| UmanDiagnostics–Quanterix: investment, 201906–201907 acquisition $16m in cash + $6.5m in common stock |
2019-06-26 |
| Forendo Pharma–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Sword Health–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Transplant Genomics–Eurofins: investment, 201906 acquisition of Transplant Genomics Inc by Eurofins |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| SQZ Biotechnologies–Erytech: drug delivery technology, 201906– license to red blood cell encapsulation from Erytech to develop immunomodulators |
2019-06-24 |
| Terns Pharmaceuticals–Genfit: elafibranor, 201906– license excl $35m upfront + $193m milestones + royalties for Greater China |
2019-06-24 |
| Avacta–JSR Corp: cell line development, 201906– CHO cell line development for clinical manufacturing of AVA004 Affimer PD-L1 antagonist by Selexis |
2019-06-20 |
| Karolinska Institutet–BGI: DNA sequencing, 201906– collab using DNBSEQ techn for shotgun metagenomics data from microbiome biobank MGI Tech |
2019-06-20 |
| BMS–Catalent: investment, 201906– acquisition of BMS manufacturing facility in Anagni Italy by Catalent |
2019-06-19 |
| Gamida Cell–Lonza: cell therapy contract manufacturing, 201906– supply multi-year future commercial production of omidubicel by Lonza in Geleen (NL) |
2019-06-19 |
| Drax Group–Deep Branch Biotechnology: carbon recycling, 201906– collab research carbon dioxide of power generation for single cell protein production |
2019-06-18 |
| Germany (govt)–Trophic Communications: public relations, 201906 service existent for German Accelerator Life Sciences by Trophic |
2019-06-18 |
| Sanofi–Alphabet: healthcare informatics, 201906– collab new virtual innovation lab using Google Cloud for future medicines + healthcare services |
2019-06-18 |
| Spero Therapeutics–Novo Group: investment, 201906– direct offering common stock up to $10m in two tranches of $5m to Novo REPAIR Fund |
2019-06-13 |
| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
| Ipsen–Debiopharm: triptorelin, 201906– strategic collab extension 15y developm + prod + distrib Decapeptyl in Europe + certain Asia + Africa |
2019-06-12 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [LSBNL] Life-Sciences-Benelux.com – The Business Web Portal 600x86px](/banner/iito-20190616-600-086-lsbnl-life-sciences-benelux-com.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
